Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$0.43 - $1.24 $17,647 - $50,890
41,041 Added 212.3%
60,373 $37,000
Q1 2022

May 16, 2022

SELL
$0.74 - $1.79 $60,665 - $146,744
-81,980 Reduced 80.92%
19,332 $23,000
Q4 2021

Feb 14, 2022

SELL
$1.69 - $2.46 $68,456 - $99,647
-40,507 Reduced 28.56%
101,312 $177,000
Q3 2021

Nov 15, 2021

BUY
$2.38 - $3.77 $279,666 - $443,001
117,507 Added 483.33%
141,819 $339,000
Q2 2021

Aug 11, 2021

SELL
$3.49 - $5.51 $60,460 - $95,455
-17,324 Reduced 41.61%
24,312 $89,000
Q1 2021

May 17, 2021

BUY
$5.37 - $10.72 $1,621 - $3,237
302 Added 0.73%
41,636 $230,000
Q4 2020

Feb 16, 2021

BUY
$3.08 - $7.79 $54,100 - $136,831
17,565 Added 73.9%
41,334 $313,000
Q3 2020

Nov 16, 2020

SELL
$2.02 - $3.08 $80,244 - $122,353
-39,725 Reduced 62.56%
23,769 $48,000
Q2 2020

Aug 14, 2020

SELL
$2.1 - $3.42 $517,878 - $843,402
-246,609 Reduced 79.52%
63,494 $186,000
Q1 2020

May 15, 2020

SELL
$2.31 - $4.43 $257,278 - $493,395
-111,376 Reduced 26.43%
310,103 $741,000
Q4 2019

Feb 14, 2020

BUY
$2.82 - $12.9 $931,434 - $4.26 Million
330,296 Added 362.23%
421,479 $1.88 Million
Q3 2019

Nov 14, 2019

SELL
$4.33 - $11.64 $74,978 - $201,558
-17,316 Reduced 15.96%
91,183 $943,000
Q2 2019

Aug 16, 2019

BUY
$4.6 - $10.13 $34,109 - $75,113
7,415 Added 7.34%
108,499 $624,000
Q2 2019

Aug 14, 2019

SELL
$4.6 - $10.13 $626,602 - $1.38 Million
-136,218 Reduced 57.4%
101,084 $581,000
Q1 2019

May 15, 2019

BUY
$7.19 - $32.37 $1.71 Million - $7.68 Million
237,302 New
237,302 $2.18 Million

Others Institutions Holding SLDB

About Solid Biosciences Inc.


  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $36.5M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.